Brought to you by 
Novo licenses rights to Xencor's XmAb-generated candidates
02 Feb 2023
Executive Summary
Xencor Inc. and Novo Nordisk AS agreed to design drug candidates using Xencor's XmAb platform, and Novo will hold development and commercialization rights to resulting products.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novo licenses rights to Xencor's XmAb-generated candidates
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice